On July 11, 2022, CytoDyn Inc. (OTCQB: CYDY), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a new, preclinical study in non-human primates that will evaluate the potential use in HIV of a gene therapy based on the experimental monoclonal antibody leronlimab. The research will be led by Oregon Health & Science University (OHSU) researcher Jonah Sacha, PhD, who also serves as a CytoDyn scientific advisor. The study is funded by a five-year grant of up to $5 million to OHSU from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant will fund the development and preclinical research of a single-injection gene therapy that codes for the leronlimab protein sequence and which will be delivered via an adeno-associated virus (AAV) vector. The study will examine if this gene-therapy approach could provide the potential for “functional cure,” i.e., sustained viral suppression in people with HIV without requiring them to take medications for the rest of their lives.